News & Updates
Filter by Specialty:

Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
15 Nov 2023
byStephen Padilla
First-line treatment with TST001 (osemitamab) in combination with capecitabine and oxaliplatin (CAPOX) is safe and well tolerated in patients with advanced gastric/gastroesophageal junction (G/GEJ) cancer, according to a study presented at ESMO 2023.
Osemitamab plus CAPOX proven safe, prolongs survival in advanced G/GEJ cancer
15 Nov 2023
Does intermittent fasting reduce acid exposure in GERD patients?
06 Nov 2023
Patients with suspected gastroesophageal reflux disease (GERD) may find it difficult to follow a time-restricted eating, reports a study. Additionally, there is weak evidence to suggest that intermittent fasting helps ease acid exposure.